東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Aberrant DNA methylation in human no...

The Ohio State University.

FindBook

Google Book

Amazon

博客來

Aberrant DNA methylation in human non-small cell lung cancer .

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Aberrant DNA methylation in human non-small cell lung cancer ./
作者:	Brena, Romulo Martin.
面頁冊數:	165 p.
附註:	Adviser: Christoph Plass.
Contained By:	Dissertation Abstracts International67-12B.
標題:	Biology, Genetics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoeng/servlet/advanced?query=3246121

Aberrant DNA methylation in human non-small cell lung cancer .
Brena, Romulo Martin.

Aberrant DNA methylation in human non-small cell lung cancer . - 165 p.

Adviser: Christoph Plass.

Thesis (Ph.D.)--The Ohio State University, 2007.

Finally, we conclude with Chapter 6, where we discuss the future steps that need to be taken in order to further the current understanding of how aberrant DNA methylation impacts the etiology of lung cancer.Subjects--Topical Terms:

1017730
Biology, Genetics.

Aberrant DNA methylation in human non-small cell lung cancer .
LDR:07780nam 2200373 a 45 001 858150
005 20100712
008 100712s2007 ||||||||||||||||| ||eng d
035 $a (UMI)AAI3246121
035 $a AAI3246121
040 $a UMI $c UMI
100 1 $a Brena, Romulo Martin. $3 1025181
245 1 0 $a Aberrant DNA methylation in human non-small cell lung cancer .
300 $a 165 p.
500 $a Adviser: Christoph Plass.
500 $a Source: Dissertation Abstracts International, Volume: 67-12, Section: B, page: 6853.
502 $a Thesis (Ph.D.)--The Ohio State University, 2007.
520 $a Finally, we conclude with Chapter 6, where we discuss the future steps that need to be taken in order to further the current understanding of how aberrant DNA methylation impacts the etiology of lung cancer.
520 $a Lung cancer is the leading cause of cancer-related death worldwide. Given its impact on human health, extensive research is being conducted in an effort to reduce the global lung cancer death toll. Specifically, much interest has been placed on the development of biomarkers and the discovery of novel prognostic factors. Over the past 2 decades it has become evident that the cancer genome is not only affected by genetic abnormalities, such as mutations, deletions and chromosomal rearrangements, but also by epigenetic changes which, together, contribute to the deregulation of transcription profiles. Epigenetic changes are defined as heritable lesions to the DNA affecting gene expression without altering the primary DNA sequence. These lesions typically involve a genomewide reduction in 5-methylcytosine, increased DNA methylation in gene promoter sequences and substitutions in histone tail modifications. Epigenetic changes have been shown to interact with one another, resulting in genomic instability, silencing of tumor suppressor genes, activation of oncogenes and derepression of transposable elements. As opposed to the irreversible nature of genetic lesions, epigenetic lesions can be reversed. Because of their reversibility, epigenetic alterations have become an attractive target for new therapies, which has resulted in the development of new anticancer compounds, several of which are currently in clinical trials.
520 $a The field of epigenetics has expanded considerably since its inception. Integrative research approaches aimed at elucidating the contribution of genetic and epigenetic alterations to the tumorigenic process are being undertaken worldwide, generating promising results. In hopes of furthering the body of knowledge currently afforded by the epigenetics field, the work presented in this thesis is focus primarily on unraveling the role of DNA methylation in the diagnosis, etiology and potential treatment of lung cancer.
520 $a Early detection would play a major role in reducing lung cancer-related death. Since standardized early detection methods for lung cancer are currently lacking, extensive efforts have been devoted in the lung cancer field to the identification of molecular markers which might be useful for disease detection or which might afford improvement in prognostic parameters. In recent months, several studies have reported important advances in these two areas. Lu and colleagues were able to identify a gene expression signature that helps predict survival of patients with stage I non-small cell lung cancer. Following a similar investigative approach, Chen and colleagues reported a 5 gene expression signature that correlates with clinical outcome in non-small cell lung cancer patients, regardless of stage. Other investigators, such as Guo et al. and Raponi et al. have focus primarily on specific lung cancer subtypes and have reported molecular classifiers that help refine the clinical prognosis of adenocarcinomas and squamous cell carcinomas, respectively. Other prominent investigators in the lung cancer field have focused their efforts on the discovery of markers which could be utilized for early detection. A landmark study on this line of research has recently been published by Shames and colleagues. These investigators reported a number of molecular markers that could help detect not only lung cancer, but also other types of common neoplasias, such as those of the breast and colon. The importance of this study resides in that it is one of the few research endeavors geared towards the discovery of pan-cancer markers. Furthermore, Shames and colleagues decided to focus on aberrant DNA methylation as a marker for neoplasias, an emerging investigative approach of great potential that still remains to be fully explored.
520 $a Following this line of investigation, we hypothesize that epigenetic abnormalities, in particular aberrant DNA methylation, is involved in the etiology of lung cancer. Furthermore, we hypothesized that different non-small cell lung cancer subtypes can be distinguished by their aberrant DNA methylation profiles. We tested our hypotheses by analyzing human primary lung tumors via Restriction Landmark Genomic Scanning (RLGS) in an effort to identify not only novel DNA methylation targets, but also targets specific to lung cancer.
520 $a In Chapter 1, we introduce DNA methylation as biological process intimately involved in the regulation of key cellular functions, from early development to adulthood. We continue to expand on how DNA methylation is involved in human cancer and particularly discuss the identification of key genes silenced by DNA methylation in lung cancer. We conclude the chapter by discussing how DNA methylation could be used as a biomarker and a prognostic marker in lung cancer.
520 $a Chapter 2 provides a synopsis of the techniques currently available for the assessment of DNA methylation, coupled with a discussion on the suitability of each of these techniques for their application in disease diagnosis and classification. We put special emphasis on addressing the applicability of these techniques in clinical settings, in an effort to highlight the current disconnect between bench work achievements and their translation into novel approaches which could directly impact patient lives.
520 $a Chapter 3 describes a novel technique, Bio-COBRA, for the quantitative analysis of DNA methylation. Specifically, we discuss how the determination of DNA methylation v levels in a quantitative and reproducible manner could aid in increasing the efficacy of treatments involving DNA demethylating agents.
520 $a In Chapter 4, we describe a genomewide DNA methylation scan of primary human lung adenocarcinomas and squamous cell carcinomas. Our scan revealed that these two lung cancer subtypes can in fact be distinguished based on their aberrant DNA methylation profiles. Also, we report the discovery a novel prognostic factor, oligodendrocyte transcription factor 1 (OLIG1), whose expression at the protein level was strongly correlated with survival in patients suffering from non-small cell lung cancer.
520 $a Chapter 5 presents a survey of lung-specific DNA methylation events, as determined by comparing NotI RLGS profiles from human cancers derived from 12 different organs. Our survey showed that lung cancer is the neoplasia with the highest number of tumor-specific aberrant DNA methylation events. We performed extensive mRNA expression and DNA methylation analyses in an effort to provide a comprehensive report of the genes most frequently silenced by lung-specific DNA methylation.
590 $a School code: 0168.
650 4 $a Biology, Genetics. $3 1017730
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0369
690 $a 0992
710 2 $a The Ohio State University. $3 718944
773 0 $t Dissertation Abstracts International $g 67-12B.
790 $a 0168
790 1 0 $a Plass, Christoph, $e advisor
791 $a Ph.D.
792 $a 2007
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoeng/servlet/advanced?query=3246121